Sara De Dosso
127 works · 9,247 citations · h-index 27
Top works
- Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC
- Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
- Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?
- Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer
- Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
- Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score
- Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant
- HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
- Treatment landscape of metastatic pancreatic cancer
- Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study
- Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options
- Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors
- Radiolabelled choline versus PSMA PET/CT in prostate cancer restaging: a meta-analysis.
- Pik3ca, braf, nras and kras mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mcrc) patients treated with egfr-targeting monoclonal antibodies (moabs): results of a european consortium
- Treatment of cancer-related anemia with epoetin alfa: a review
- Adjuvant therapy for colon cancer: Present and perspectives